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Purpose of the study
To demonstrate the real-life efficacy and tolerability of
FPV/r in HIV-infected patients without HAART or without
prior virological treatment failure under a PI-containing
ART regime.
Methods
Prospective single-arm observational study. Data were
collected at enrolment visit and at approx. weeks 4, 12, 24,
36 and 48. Demographics, current laboratory findings,
concomitant medication and conditions, and prior
antiretroviral treatment were documented. Routine effi-
cacy – viral load (VL) and CD4 cell count – and safety
parameters were assessed.
Summary of results
In total 285 patients were included with a mean observa-
tion period of 312 days per patient. 74 patients (27%)
were ART-naïve; 27% of the patients stopped the previous
ART due to virologic failure, 46% of the patients due to
drug intolerability. The majority of the patients were clas-
sified as well compliant (71.6% were graded 1 or 2 on a 6-
point-scale at last visit). The median VL decreased in well-
compliant patients from 5,900 copies/ml at entry to <50
copies/ml at week 12 with sustained suppression until last
visit; in patients with poor compliance, the median VL
decreased from 11,048 copies/ml at entry to <50 copies/
ml at week 12. In parallel the CD4 T-cell count increased
from a median of 297 cells/μl at entry to a median of 425
cells/μl at last visit (whole population). In 91.2% of the
ART-naïve patients and in 70% of the patients without
any virological failure in a previous ART the VL decreased
<400 copies/ml at week 48.
Adverse drug reactions were reported in 100 patients
(35.1%), predominantly diarrhoea (21.4%) and nausea
(8.4%). Serious adverse drug reactions were observed in
11 patients. In 19% of the patients therapy with FPV/r was
stopped, mostly due to drug intolerability.
Conclusion
Fosamprenavir/ritonavir demonstrated good efficacy and
tolerability in ART-naïve patients as well as in HIV
patients with any virological failure in a previous ART.
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